NCO-700

NCO-700 is a dual cathepsin B and calcium-activated neutral protease (CANP) inhibitor with IC₅₀ values of 0.8 and 46 μM, respectively. NCO-700 reduces the degradation of myocardial fibrin by inhibiting protease activity. NCO-700 also has inhibitory effects on hormone-independent tumor cells, such as prostate cancer cells, and induces apoptosis. NCO-700 can be used to study myocardial ischemia and refractory hormone-independent tumors^[1][2]. In Vitro:NCO-700 (7 days) inhibits HS-578T, PC-3, DU-145, MCF-7, LNCaP and T47D cells proliferation with IC₅₀s of 7.5, 10, 11.5, 72 and >100 μM^[2].
In Vivo:NCO-700 (total dose: 20-40 mg/kg, i.p., 4 administrations of medication) reduces the infarct area in the rabbit and doy myocardial infarction model^[1][3].
NCO-700 (10-100 mg/kg, i.p., once daily for 5 days) demonstrates significant anti-tumor activity in xenograft models of prostate cancer and breast cancer in mice^[2].